journal article·2026-04

Burden, Trends and Prediction of NAFLD/MAFLD Attributable to Smoking From 1990 to 2021: GBD 2021 Analysis

Lijuan Chen, Ziyi Zhu, Yishu Wang, Lin Guo, Zhenzhen Fu, Xianyong Yin, John Zhong Li, Yingyun Gong, Hongwen Zhou

Advanced Biology· Volume 10· Issue 4
Publisher page

Abstract

ABSTRACT Smoking is a risk factor for non‐alcoholic fatty liver disease (NAFLD, recently proposed as metabolic dysfunction‑associated fatty liver disease, MAFLD), but the global smoking‐attributable NAFLD/MAFLD burden remains unclear. Using GBD 2021 data, this study quantified the burden by age, sex, socio‐demographic index (SDI), and region, computed average annual percent changes (AAPC) via Joinpoint regression, and projected 2022–2036 burden using the Bayesian age‐period‐cohort (BAPC) model. During 1990–2021, the AAPC of the age‐standardized DALY rate (ASDR) and mortality rate (ASMR) was 0.0223 [95% uncertainty interval (UI): −0.1432, 0.1880, p = 0.79] and 0.2660 (95%UI: 0.1666, 0.3655, p < 0.001), suggesting that the death‐related burden increased mostly. Notably, males contributed the most to this trend, with the sharpest upward trend recorded in low‐middle SDI regions. Global cross‐country inequality revealed that this death‐related burden is widening, especially among females. In contrast to this historical trajectory, predictive models suggest a steady decline by 2036. In conclusion, global ASMR of smoking‐attributable NAFLD/MAFLD increased during 1990–2021, especially in low‐middle SDI regions and male populations. Despite a projected gradual burden decline over the next 15 years, it still emphasizes the need for strengthened tobacco control and NAFLD/MAFLD prevention in low‐middle SDI regions and male populations.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Nutritional Studies and Diet · Diabetes, Cardiovascular Risks, and Lipoproteins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Endocrinology and Metabolism The First Affiliated Hospital with Nanjing Medical University Nanjing China

Department of Developmental Molecular and Chemical Biology Tufts University School of Medicine Medford Massachusetts USA

Department of Epidemiology and Biostatistics School of Public Health Nanjing Medical University Nanjing China

Department of Biochemistry and Molecular Biology Nanjing Medical University Nanjing China

Funding

National Natural Science Foundation of China · Key Research and Development Program of Sichuan Province · China Postdoctoral Science Foundation

References (38)

Show source-provided references
1. 10.1097/HEP.000000000000000410.1097/HEP.0000000000000004 ↗
2. 10.1097/HC9.000000000000025110.1097/HC9.0000000000000251 ↗
3. 10.1111/apt.1709610.1111/apt.17096 ↗
4. 10.1002/hep.3117310.1002/hep.31173 ↗
5. 10.1002/hep.2946610.1002/hep.29466 ↗
6. 10.1002/hep.2698610.1002/hep.26986 ↗
7. 10.1038/s41395‐018‐0283‐510.1038/s41395‐018‐0283‐5 ↗
8. 10.1111/liv.1370110.1111/liv.13701 ↗
9. 10.2188/jea.je2012006710.2188/jea.je20120067 ↗
10. 10.14309/ajg.000000000000114110.14309/ajg.0000000000001141 ↗
11. 10.1038/s41586‐022‐05299‐410.1038/s41586‐022‐05299‐4 ↗
12. 10.1016/j.jhep.2009.03.02610.1016/j.jhep.2009.03.026 ↗
13. 10.1136/tc‐2024‐05871710.1136/tc‐2024‐058717 ↗
14. 10.1016/S0140‐6736(21)01169‐710.1016/S0140‐6736(21)01169‐7 ↗
15. 10.1136/tobaccocontrol‐2021‐05653510.1136/tobaccocontrol‐2021‐056535 ↗
16. 10.1016/S2468‐2667(21)00102‐X10.1016/S2468‐2667(21)00102‐X ↗
17. 10.1002/hep.2351610.1002/hep.23516 ↗
18. 10.1016/j.intimp.2024.11306710.1016/j.intimp.2024.113067 ↗
19. 10.1055/s‐0034‐137561010.1055/s‐0034‐1375610 ↗
20. 10.26719/2021.27.1.7610.26719/2021.27.1.76 ↗
21. 10.1038/s41575‐022‐00688‐610.1038/s41575‐022‐00688‐6 ↗
22. 10.1002/hep.3062610.1002/hep.30626 ↗
23. 10.1038/s41467‐022‐28138‐610.1038/s41467‐022‐28138‐6 ↗
24. 10.1053/j.gastro.2016.09.01710.1053/j.gastro.2016.09.017 ↗
25. 10.1097/MCG.000000000000173910.1097/MCG.0000000000001739 ↗
26. 10.1016/S0140‐6736(18)32278‐510.1016/S0140‐6736(18)32278‐5 ↗
27. 10.1016/S0140‐6736(23)01301‐610.1016/S0140‐6736(23)01301‐6 ↗
28. 10.1097/HJH.000000000000014210.1097/HJH.0000000000000142 ↗
29. 10.1007/s12072‐025‐10782‐x10.1007/s12072‐025‐10782‐x ↗
30. 10.1002/hep.3222810.1002/hep.32228 ↗
31. 10.1016/S2468‐2667(24)00166‐X10.1016/S2468‐2667(24)00166‐X ↗
32. 10.1016/j.clpt.2006.01.00810.1016/j.clpt.2006.01.008 ↗
33. 10.1016/j.cjca.2023.01.01810.1016/j.cjca.2023.01.018 ↗
34. 10.1186/s12931‐025‐03228‐310.1186/s12931‐025‐03228‐3 ↗
35. 10.1016/S0140‐6736(24)00757‐810.1016/S0140‐6736(24)00757‐8 ↗
36. 10.1016/S0140‐6736(24)00367‐210.1016/S0140‐6736(24)00367‐2 ↗
37. 10.1136/gutjnl‐2019‐32023410.1136/gutjnl‐2019‐320234 ↗
38. 10.1097/JS9.000000000000269710.1097/JS9.0000000000002697 ↗